LINC01227: A Potential Drug Target and Biomarker (G101928276)

Target Name: LINC01227

NCBI ID: G101928276

LINC01227

Other Name(s): Long intergenic non-protein coding RNA 1227, transcript variant 1 | long intergenic non-protein coding RNA 1227

LINC01227: A Potential Drug Target and Biomarker

LINC01227 is a long intergenic non-protein coding RNA (lncRNA) with a length of approximately 291 nucleotides. It is located between the intron and the 5' end of exon 18 of the HIC1 gene, which is located on chromosome 16. LINC01227 is a non-coding RNA molecule that is involved in the regulation of gene expression. The discovery of LINC01227 as a potential drug target and biomarker has significant implications for the development of new therapeutics for various diseases.

Expression and Function

LINC01227 is a highly expressed gene in most tissues, with the highest expression levels observed in the liver, lung, and heart. It is expressed in various cell types, including muscle, nerve, liver, and blood cells. The expression level of LINC01227 is regulated by various factors, including DNA binding proteins, RNA binding proteins, and post-transcriptional regulatory factors.

LINC01227 is involved in the regulation of gene expression by binding to specific DNA sequences. It has been shown to interact with various transcription factors, including AP1, a key transcription factor that regulates gene expression in many organisms. LINC01227 has been shown to physically interact with AP1 and enhance its transcriptional activity.

Additionally, LINC01227 has been shown to play a role in the regulation of cell apoptosis. It has been shown to be involved in the regulation of cell death and has been shown to promote the apoptosis of cancer cells. This suggests that LINC01227 may be a potential drug target for cancer therapies.

Drug Interaction with LINC01227

Given its potential involvement in drug targeting and cell apoptosis, LINC01227 is an attractive target for drug development. Several studies have shown that LINC01227 can be inhibited by various small molecules, including inhibitors of AP1 signaling, DNA-binding proteins, and RNA-binding proteins.

One potential drug that has been shown to interact with LINC01227 is the small molecule inhibitor, rapamycin. Rapamycin is an inhibitor of the activity of the protein SIRT1, which is a DNA-binding protein that is involved in the regulation of cell apoptosis. Rapamycin has been shown to inhibit the transcriptional activity of LINC01227 and has been shown to enhance the apoptosis of cancer cells.

Another potential drug that may interact with LINC01227 is the small molecule inhibitor, curcumin. Curcumin is an antioxidant that is derived from the curcuma plant, and has been shown to have anti-inflammatory and anti-cancer properties. Curcumin has been shown to inhibit the activity of several transcription factors, including AP1, and has been shown to enhance the transcriptional activity of LINC01227.

Conclusion

LINC01227 is a long intergenic non-protein coding RNA molecule that is involved in the regulation of gene expression and has been shown to play a role in the regulation of cell apoptosis. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapeutics for various diseases. The discovery of LINC01227 as a potential drug target and biomarker has significant implications for the development of new therapeutics for cancer, as it may be a valuable target for cancer therapies. Further research is needed to fully understand the mechanisms of LINC01227's function and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1227

The "LINC01227 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01227 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets